ClinicalTrials.gg
TerminatedNCT02355184Updated Oct 7, 2025Results posted

An Extension of Protocol PRO 140_CD01 Study

A Phase 2 interventional study of PRO 140 350mg weekly subcutaneous (SC) injection. in HIV and Human Immunodeficiency Virus, sponsored by CytoDyn, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
FDA required the sponsor to halt enrollment in the trial and transition participants to available therapies for the treatment of their disease. The trial was subsequently terminated once participants were transitioned.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an extension of Protocol PRO 140_CD 01 to further evaluate the long-term suppression of HIV-1 replication following substitution of stable combination antiretroviral therapy with a PRO 140 (Monoclonal CCR5 antibody) monotherapy in adult subjects with HIV-1 infection

Read the detailed description

This study is a Phase 2b, multi-center, extension study designed to evaluate the long-term efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in patients who were stable on combination antiretroviral therapy and completed 12 weeks of treatment under PRO 140_CD 01 Treatment Substitution Study without experiencing virologic failure.

Consenting patients will continue to receive PRO 140 monotherapy until investigational product (IP) receives marketing approval or investigational new drug (IND) is withdrawn by Sponsor. There is one week overlap of existing retroviral regimen and PRO 140 at the end of the treatment extension phase in subjects who do not experience virologic failure.

PRO 140 will be administered as a 350 mg subcutaneous injection weekly during treatment extension phase. Study participants will be monitored for viral rebound on a weekly basis following initiation of PRO 140 monotherapy and will re-initiate their previous antiretroviral regimen if plasma HIV-1 RNA levels rise above 400 copies/ml on two consecutive blood draws at least 3 days apart.

.

02

Conditions studied

  • HIV
  • Human Immunodeficiency Virus

Browse trials for

03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 20 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who have completed 12 weeks of treatment in PRO 140_CD01 study without experiencing virologic failure.
  2. Both male and female patients and their partners of must agree to use appropriate methods (birth control pills, barriers, or abstinence) throughout the study duration (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative urine pregnancy test prior to receiving the first dose of study drug.
  3. Willing and able to participate in all aspects of the study, including use of SC medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written .

Exclusion criteria

Exclusion Criteria:

  1. Not currently enrolled in PRO140_CD01 Treatment Substitution Study
  2. Any acquired immune deficiency syndrome (AIDS)-defining illness according to the 1993 Centers for Disease Control and Prevention (CDC) AIDS surveillance definition
  3. Laboratory test values ≥ grade 4 DAIDS laboratory abnormality.
  4. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
  5. Unexplained temperature >38.5C (101.3F) for seven consecutive days within 14 days prior to the first study dose
  6. Diagnosed with either substance dependence or substance abuse or any history of a concomitant condition (e.g., medical, psychologic, or psychiatric) that in the opinion of the primary care provider and/or site investigator would interfere with the subject's successful completion of the study requirements
  7. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    PRO 140

    PRO 140 350mg weekly subcutaneous (SC) injection.

    Drug: PRO 140 350mg weekly subcutaneous (SC) injection.

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Virologic Failure After Initiating PRO 140 Monotherapy

    Virologic failure (VF) is defined as two consecutive HIV-1 RNA levels of ≥ 400 copies/ml separated by at least 3 days. The time to VF will be compared to a historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days). The statistical comparison will be conducted using Wilcoxon rank sum test and the median time to Virologic Failure for this study will be compared to 30 days.

    Time frame: From treatment extension visit 1 (TE1) until virologic failure, assessed up to 125 weeks.

Secondary outcomes

  1. Proportion of Participants With Virologic Failure After Initiating PRO 140 Monotherapy.

    Virologic failure is defined as two consecutive HIV-1 RNA levels of ≥ 400 copies/ml separated by at least 3 days.

    Time frame: From treatment extension visit 1 (TE1) until virologic failure, assessed up to 125 weeks.

  2. Mean Change in Viral Load (HIV-1 RNA Levels)

    Mean change from baseline of HIV-1 RNA levels was assessed for each week during the treatment phase up until week 58. Weighted mean change in viral load (HIV-1 RNA levels) were calculated from baseline to week 58.

    Time frame: From treatment extension visit TE2 (defined as baseline), until week 58 of extension treatment.

  3. Mean Change in CD4 Cell Count

    Mean change in CD4 cell count from baseline (TE2 visit) was assessed for each week during the treatment phase up until week 58. The average mean change was calculated from baseline to week 58.

    Time frame: From treatment extension visit TE2 (defined as baseline), until week 58 of extension treatment.

  4. Change in Quality of Life Metrics (up to TE107)

    A Quality of Life (QoL) assessment using ACTG SF-21 was planned to be performed at screening visit (SV1), once every four weeks from treatment visit 4 (TE4) through treatment visit 107 (TE107), and at end of treatment (EOT). The ACTG SF-21 has 8 QoL domains with a standard score ranging from 0 (worst) to 100 (best).

    Time frame: From TE4 (baseline) through every fourth weekly visits to treatment visit 107 (TE107) or EOT, up to 125 weeks.

Other outcomes

  1. Tolerability of Repeated Subcutaneous Administration of PRO 140 as Assessed by Study Participants(Using Visual Analogue Scale) and by Investigator-evaluation of Injection Site Reactions.

    Tolerability of repeated subcutaneous administration of PRO 140 was planned to be assessed by the study participants using a Visual Analogue Scale, and by investigator-evaluation of injection site reactions. Injection site reaction assessment was not completed when subjects performed self-administration.

    Time frame: From TE1 (first treatment administration) weekly until last treatment visit (up to 125 weeks)

  2. Number of Participants With Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale

    The Division of AIDS (DAIDS) grading table provides an adverse event severity grading scale ranging from grades 1 to 5 with descriptions for each adverse event based on the following general guidelines: * Grade 1 indicates a mild event * Grade 2 indicates a moderate event * Grade 3 indicates a severe event * Grade 4 indicates a potentially life-threatening event * Grade 5 indicates death (Note: This grade is not specifically listed on each page of the grading table).

    Time frame: From the first treatment visit (TE1) until final study visit, up to a 125 weeks.

  3. Number of Participants With at Least One Treatment-related Serious Adverse Event.

    Treatment-related serious adverse events are defined as serious events with an onset on or after the first treatment. A serious adverse event is defined as any adverse event that: * Results in death * Is life threatening (the subject is at immediate risk of dying from the AE) * Requires subject hospitalization or prolongs existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse event when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.

    Time frame: From the first treatment visit (TE1) until final study visit up to 125 weeks.

07

Results

Posted Oct 7, 2025
Limitations and caveats
Certain lab data were not collected or were otherwise unavailable for analysis or reporting.

Participant flow

Participant flow — Overall Study
MilestonePRO 140
Started20
Completed8
Not completed12
Withdrew: Lost to follow-up2
Withdrew: Study terminated10

Outcome measures

PrimaryTime to Virologic Failure After Initiating PRO 140 Monotherapy

Virologic failure (VF) is defined as two consecutive HIV-1 RNA levels of ≥ 400 copies/ml separated by at least 3 days. The time to VF will be compared to a historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days). The statistical comparison will be conducted using Wilcoxon rank sum test and the median time to Virologic Failure for this study will be compared to 30 days.

Time frame:
From treatment extension visit 1 (TE1) until virologic failure, assessed up to 125 weeks.
Reported as:
Mean · days
Time to Virologic Failure After Initiating PRO 140 Monotherapy
daysPRO 140
Time to Virologic Failure After Initiating PRO 140 Monotherapy228.8 ± 225.6
SecondaryProportion of Participants With Virologic Failure After Initiating PRO 140 Monotherapy.

Virologic failure is defined as two consecutive HIV-1 RNA levels of ≥ 400 copies/ml separated by at least 3 days.

Time frame:
From treatment extension visit 1 (TE1) until virologic failure, assessed up to 125 weeks.
Reported as:
Number · proportion of participants
Proportion of Participants With Virologic Failure After Initiating PRO 140 Monotherapy.
proportion of participantsPRO 140
Proportion of Participants With Virologic Failure After Initiating PRO 140 Monotherapy.0.3
SecondaryMean Change in Viral Load (HIV-1 RNA Levels)

Mean change from baseline of HIV-1 RNA levels was assessed for each week during the treatment phase up until week 58. Weighted mean change in viral load (HIV-1 RNA levels) were calculated from baseline to week 58.

Time frame:
From treatment extension visit TE2 (defined as baseline), until week 58 of extension treatment.
Reported as:
Mean · copies/mL
Mean Change in Viral Load (HIV-1 RNA Levels)
copies/mLPRO 140
Mean Change in Viral Load (HIV-1 RNA Levels)147.34 ± 263.60
SecondaryMean Change in CD4 Cell Count

Mean change in CD4 cell count from baseline (TE2 visit) was assessed for each week during the treatment phase up until week 58. The average mean change was calculated from baseline to week 58.

Time frame:
From treatment extension visit TE2 (defined as baseline), until week 58 of extension treatment.
Reported as:
Mean · cells/uL
Mean Change in CD4 Cell Count
cells/uLPRO 140
Mean Change in CD4 Cell Count22 ± 111
SecondaryChange in Quality of Life Metrics (up to TE107)

A Quality of Life (QoL) assessment using ACTG SF-21 was planned to be performed at screening visit (SV1), once every four weeks from treatment visit 4 (TE4) through treatment visit 107 (TE107), and at end of treatment (EOT). The ACTG SF-21 has 8 QoL domains with a standard score ranging from 0 (worst) to 100 (best).

Time frame:
From TE4 (baseline) through every fourth weekly visits to treatment visit 107 (TE107) or EOT, up to 125 weeks.
Reported as:
Mean · score
Change in Quality of Life Metrics (up to TE107)
scorePRO 140
Change in Quality of Life Metrics (up to TE107)1.4 ± 5.9
Other pre-specifiedTolerability of Repeated Subcutaneous Administration of PRO 140 as Assessed by Study Participants(Using Visual Analogue Scale) and by Investigator-evaluation of Injection Site Reactions.

Tolerability of repeated subcutaneous administration of PRO 140 was planned to be assessed by the study participants using a Visual Analogue Scale, and by investigator-evaluation of injection site reactions. Injection site reaction assessment was not completed when subjects performed self-administration.

Time frame:
From TE1 (first treatment administration) weekly until last treatment visit (up to 125 weeks)

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale

The Division of AIDS (DAIDS) grading table provides an adverse event severity grading scale ranging from grades 1 to 5 with descriptions for each adverse event based on the following general guidelines: * Grade 1 indicates a mild event * Grade 2 indicates a moderate event * Grade 3 indicates a severe event * Grade 4 indicates a potentially life-threatening event * Grade 5 indicates death (Note: This grade is not specifically listed on each page of the grading table).

Time frame:
From the first treatment visit (TE1) until final study visit, up to a 125 weeks.
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale
ParticipantsPRO 140
Number of Participants With Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale7
Other pre-specifiedNumber of Participants With at Least One Treatment-related Serious Adverse Event.

Treatment-related serious adverse events are defined as serious events with an onset on or after the first treatment. A serious adverse event is defined as any adverse event that: * Results in death * Is life threatening (the subject is at immediate risk of dying from the AE) * Requires subject hospitalization or prolongs existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse event when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.

Time frame:
From the first treatment visit (TE1) until final study visit up to 125 weeks.
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-related Serious Adverse Event.
ParticipantsPRO 140
Number of Participants With at Least One Treatment-related Serious Adverse Event.0

Adverse events

Collected over Adverse events were reported from the time of the first treatment and continued up until the final study visit to evaluate safety of PRO140 (up to a maximum of 91 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PRO 1400/20 (0%)4/20 (20%)15/20 (75%)
Most frequent serious events
Most frequent serious events
EventPRO 140
AsthmaRespiratory, thoracic and mediastinal disorders1/20
Intestinal PerforationGastrointestinal disorders1/20
Suicide AttemptPsychiatric disorders1/20
SyncopeNervous system disorders1/20
HypertensionVascular disorders1/20
Chest PainGeneral disorders1/20
Bile duct stoneHepatobiliary disorders1/20
Most frequent other events
Showing 10 of 92
Most frequent other events
EventPRO 140
NasopharyngitisInfections and infestations5/20
Upper respiratory tract infectionInfections and infestations5/20
DiarrhoeaGastrointestinal disorders4/20
SinusitisInfections and infestations4/20
InfluenzaInfections and infestations3/20
GastroenteritisInfections and infestations3/20
LymphadenopathyBlood and lymphatic system disorders3/20
BronchitisInfections and infestations2/20
Fungal skin infectionInfections and infestations2/20
Pain in extremityMusculoskeletal and connective tissue disorders2/20

Baseline characteristics

Subjects with HIV-1 infection who did not experience virologic failure while in the treatment phase of the PRO 140\_CD 01 study.

Age, Continuous
Age, Continuous(years)PRO 140
Mean56.05 (32 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)PRO 140
Female2
Male18
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PRO 140
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White16
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)PRO 140
United States20
Time since HIV Diagnosis
Time since HIV Diagnosis(years)PRO 140
Mean10 (2 to 37)
08

Study locations

1 site
  • CD01-Extension Investigational Site
    San Francisco, California 94115, United States
09

References and documents

Publications

  • Chang XL, Reed JS, Webb GM, Wu HL, Le J, Bateman KB, Greene JM, Pessoa C, Waytashek C, Weber WC, Hwang J, Fischer M, Moats C, Shiel O, Bochart RM, Crank H, Siess D, Giobbi T, Torgerson J, Agnor R, Gao L, Dhody K, Lalezari JP, Bandar IS, Carnate AM, Pang AS, Corley MJ, Kelly S, Pourhassan N, Smedley J, Bimber BN, Hansen SG, Ndhlovu LC, Sacha JB. Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species. PLoS Pathog. 2022 Mar 31;18(3):e1010396. doi: 10.1371/journal.ppat.1010396. eCollection 2022 Mar. PubMed 35358290 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2014 to primary completion in Jun 2022, 91 months.

Results were first posted in Oct 2025, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2015
First posted
Feb 4, 2015
StartActual
Nov 18, 2014
Primary completionActual
Jun 2022
CompletionActual
Jul 15, 2022
Results first posted
Oct 7, 2025
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02355184
Lead sponsor
CytoDyn, Inc.
Responsible party
Sponsor
First posted
Feb 4, 2015
Start date
Nov 18, 2014
Primary completion
Jun 2022
Completion
Jul 15, 2022
Results posted
Oct 7, 2025
Last update
Oct 7, 2025

Study contacts

Jacob Lalezari, MD
principal investigator · CytoDyn, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion